The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...

Popular heartburn drug Ranitidine, long under scrutiny, will continue to be available in India as the government confirmed it had no plans to ban its manufacture or sale. The government had ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com .

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise ...

U.S. Sen. Richard Blumenthal (D-CT) called on U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D. to ...

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.